These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16553569)

  • 1. Cost implications of antimuscarinic drugs in the treatment of overactive bladder syndrome.
    Perimenis P; Konstantinopoulos A; Giannitsas K; Athanasopoulos A
    Expert Opin Pharmacother; 2006 Apr; 7(5):539-44. PubMed ID: 16553569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of cost-effectiveness comparisons for overactive bladder treatments: which is the most cost-effective for improving quality of life?
    Giannitsas K; Athanasopoulos A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):413-23. PubMed ID: 25656409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis.
    Chapple C; Khullar V; Gabriel Z; Dooley JA
    Eur Urol; 2005 Jul; 48(1):5-26. PubMed ID: 15885877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
    Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
    Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations.
    Getsios D; El-Hadi W; Caro I; Caro JJ
    Pharmacoeconomics; 2005; 23(10):995-1006. PubMed ID: 16235973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.
    Hashim H; Abrams P
    Drugs; 2004; 64(15):1643-56. PubMed ID: 15257626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Overactive bladder--treatment with antimuscarinic agents].
    Höfner K
    Urologe A; 2003 Jun; 42(6):793-800. PubMed ID: 12851770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimuscarinic drug therapy for overactive bladder syndrome in the elderly - are the concerns justified?
    Khastgir J
    Expert Opin Pharmacother; 2019 May; 20(7):813-820. PubMed ID: 30724647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Cardozo L; Thorpe A; Warner J; Sidhu M
    BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Overactive bladder: modulating the effects of antimuscarinic therapy].
    Palleschi G; Tubaro A; Miano L
    Minerva Urol Nefrol; 2005 Dec; 57(4):237-45. PubMed ID: 16247346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more cost-effective as the first-line treatment?
    Yamanishi Y; Yamanishi T; Tajima H; Ikeda S
    Int J Urol; 2018 Oct; 25(10):863-870. PubMed ID: 30112772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic management of urinary incontinence, voiding dysfunction, and overactive bladder.
    Saks EK; Arya LA
    Obstet Gynecol Clin North Am; 2009 Sep; 36(3):493-507. PubMed ID: 19932412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation.
    Pradelli L; Iannazzo S
    J Med Econ; 2009 Mar; 12(1):25-35. PubMed ID: 19450062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimuscarinic management of overactive bladder.
    Winder A
    Br J Community Nurs; 2005 Jul; 10(7):313-6. PubMed ID: 16010231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder.
    Ko Y; Malone DC; Armstrong EP
    Pharmacotherapy; 2006 Dec; 26(12):1694-702. PubMed ID: 17125433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.
    Chapple CR; Khullar V; Gabriel Z; Muston D; Bitoun CE; Weinstein D
    Eur Urol; 2008 Sep; 54(3):543-62. PubMed ID: 18599186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives.
    Wielage RC; Perk S; Campbell NL; Klein TM; Posta LM; Yuran T; Klein RW; Ng DB
    J Med Econ; 2016 Dec; 19(12):1135-1143. PubMed ID: 27326725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults.
    Garely AD; Burrows L
    Drug Saf; 2004; 27(13):1043-57. PubMed ID: 15471509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The medical treatment of overactive bladder, including current and future treatments.
    Athanasopoulos A; Cruz F
    Expert Opin Pharmacother; 2011 May; 12(7):1041-55. PubMed ID: 21299469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Darifenacin in the treatment of overactive bladder.
    Haab F
    Drugs Today (Barc); 2005 Jul; 41(7):441-52. PubMed ID: 16193097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.